Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine

Trial Profile

Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2015

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Nov 2012 Results were presented at IDWeek, according to a Sanofi Pasteur media release.
    • 02 May 2012 Primary endpoints 'Geometric-mean-antibody-titre and Seroconversion rates' have been met.
    • 02 May 2012 According to a Sanofi media release, immunogenicity was assessed at 28 days post-vaccination, while the ClinicalTrials.gov record reports that the endpoints will be assessed at 21 days.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top